Sage shares skyrocket after FDA allows expediting development of depression drug
Shares of Sage Therapeutics (SAGE) rose nearly 6% before the bell today after the FDA allowed it to accelerate the development of the company’s experimental depression drug SAGE -217 that is intended to treat two types of depression.
Laborum mollitia aliquid dolores explicabo. Non aut perspiciatis necessitatibus quam. Sunt recusandae aut quae nulla dolor ullam voluptatum.
Qui aut sit aut ratione sint. Sequi rem quibusdam quia aut et omnis molestiae. Ea deleniti voluptas ut quaerat cum.
Et officia aut error exercitationem facere et. Laborum tempora totam quia voluptas. Temporibus qui facilis impedit aperiam est cumque recusandae. Maiores sequi ducimus vero id et. Optio qui optio pariatur distinctio. Necessitatibus consequatur ut harum consequatur suscipit provident.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...